Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China
暂无分享,去创建一个
A. Ou | L. xilinx Wang | Yuxia Li | H. Weng | Xinying Chen | Jinghua Yang | Jianwen Guo | Tengfei Huang | Lijun Deng | Junbin Hong | Bo Yu
[1] M. Kiso,et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB , 2022, The Lancet Infectious Diseases.
[2] S. Harrison,et al. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature , 2022, Viruses.
[3] G. Lippi,et al. In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT‐qPCR assays for SARS‐CoV‐2 detection using whole genome sequencing , 2022, Journal of medical virology.
[4] B. Grunau,et al. The Relationship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough COVID-19 Among Fully Vaccinated Adults , 2022, The Journal of infectious diseases.
[5] M. Ajelli,et al. Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study , 2022, The Lancet Regional Health - Western Pacific.
[6] D. Barouch. Covid-19 Vaccines — Immunity, Variants, Boosters , 2022, The New England journal of medicine.
[7] L. Abu-Raddad,et al. COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status. , 2022, JAMA internal medicine.
[8] Lu Lu,et al. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages , 2022, Signal Transduction and Targeted Therapy.
[9] Yingxia Liu,et al. Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children , 2022, Signal Transduction and Targeted Therapy.
[10] R. Dagan,et al. Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities. , 2022, JAMA internal medicine.
[11] R. Link-Gelles,et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. , 2022, JAMA.
[12] Jiahui Chen,et al. Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant , 2022, The journal of physical chemistry letters.
[13] Qiuying Li,et al. Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody. , 2022, Archives of pathology & laboratory medicine.
[14] N. Volkow,et al. Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US. , 2022, JAMA pediatrics.
[15] P. Zheng,et al. Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization , 2022, Allergy.
[16] Q. Ye,et al. The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant , 2022, Journal of medical virology.
[17] S. Karim,et al. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.
[18] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[19] Youchun Wang. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines , 2021, EBioMedicine.
[20] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[21] A. Fiore-Gartland,et al. Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.
[22] P. Zheng,et al. Characteristics of COVID-19 Patients Based on the Results of Nucleic Acid and Specific Antibodies and the Clinical Relevance of Antibody Levels , 2021, Frontiers in Molecular Biosciences.
[23] X. Tang,et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.
[24] Satoshi Mimura,et al. Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis , 2020, The Lancet Infectious Diseases.
[25] Y. Leo,et al. Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] S. Ng,et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis , 2020, The Lancet Gastroenterology & Hepatology.
[27] X. Tang,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[28] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[29] Seung‐Jung Park,et al. Predictors for functionally significant in-stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion imaging. , 2013, JACC. Cardiovascular imaging.
[30] Akiko Maehara,et al. A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.
[31] P. Fratino,et al. IDDM in the Province of Pavia, Italy, From a Population-Based Registry: A descriptive study , 1995, Diabetes Care.
[32] OUP accepted manuscript , 2022, Clinical Infectious Diseases.
[33] Michel Dückers,et al. A Systematic Review of the Literature , 2009 .
[34] S. Jun,et al. retrospective analysis , 2003 .